NICE's Rejection Of Takeda's Mepact In Osteosarcoma Causes Storm Of Protest
This article was originally published in PharmAsia News
Executive Summary
LONDON - Feelings are running high over NICE's initial rejection of the use of Takeda's osteosarcoma therapy, Mepact (mifamurtide), in the U.K. National Health Service